Article By:
ChinaBio® Today
Saturday, January 13, 2024 1:20 PM EDT
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
Daily Stock Pick: Novartis
I like $NVS.
OncoSec Raising Its Profile In Fight Against Cancer
More good news on the war against #Cancer, thanks. #Novartis also has made great progress against B-cell acute lymphoblastic leukemia: www.talkmarkets.com/.../finally-a-cure-for-cancer $ONCS $NVS
Finally… A Cure for Cancer?
Lot of good news against the war on #Cancer. Also just read this about #OncoSec: www.talkmarkets.com/.../oncosec-raising-its-profile-in-fight-against-cancer $ONCS $NVS
Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Yes it does indeed. #Novartis has been doing very well lately. $NVS
Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Triple the effectiveness over a placebo looks very promising! $NVS
Novartis-Backed Ionis Subsidiary Akcea Maps A $100M IPO As It Steers A Lead Drug To Regulators
Sounds good to me! $NVS $IONS